Coming soon: GLOBAL PHARMA REPORT 2023 – sign up here to be the first one notified!
The results are based on Caliber’s real-time tracking study that measures public perceptions of the OMX S30 companies in Sweden on a daily basis.
The 2022 full-year results are based on approx. 12,000 evaluations representing the Swedish population.
How it works
Book a demo
© 2022 Group Caliber | All Rights Reserved | VAT: DK39314320